Orin is the program director for the postgraduate programs in Pharmaceutical and Medical Device Development at the University of Sydney. She has academic appointments with UNSW and Arizona State University, USA, as well as Board appointments with ARCS Australia and the Association of Graduate Regulatory Educators (USA). Orin developed and delivers the Pharmaceutical and Therapeutics Specialisation course within the NSWHealth Commercialisation training program at CICADA Innovations. Orin received The Organisation for Professionals in Regulatory Affairs (TOPRA), UK award for excellence in regulatory education in 2017; became a Senior Fellow of the Higher Education Academy (UK) in 2018 and was elected a Fellow of the Regulatory Affairs Professionals Society (RAPS), USA in 2021. Her research focuses on regulatory science, workforce development and pharmaceutical policy. Orin is also a regulatory consultant and has been the regulatory responsible person for bringing several new medicines to the Australian and New Zealand markets.

Tzu-Chiao Wei has just completed her first year of master degree in pharmacology at National Yang Ming Chiao Tung University(NYCU), instructed by A/prof. Yen. She was honored with a scholarship award for academic excellence in her first year. In addition to academic pursuits, Tzu-Chiao is a licensed respiratory therapist with a specialization in critical care medicine and used to work as a Clinical Research Coordinator (CRC) in Cardiology Department at Taipei Veterans General Hospital Her current research focuses on the preclinical study of migraine, which she has made some interesting discovery and is eager to share.

Jasmine Lee is a PhD candidate at the University of Sydney's School of Pharmacy and a registered pharmacist. Her research revolves around the economics and usage patterns of anticancer drugs, with a focus on forecasting future trends to inform healthcare budgeting and policy.

Yingshan Dong is an Honours student in the Drug Discovery Biology Theme at the Monash Institute of Pharmaceutical Science. She completed her Bachelor of Pharmaceutical Science at Monash University, where she developed a keen interest in pharmacology. Following her undergraduate studies, Yingshan pursued Honours in Analytical and Structural Neuropharmacology under the supervision of Celine Valant and Vi Pham. Her Honours project aims to unravel the mechanisms underlying the internalisation and subcellular trafficking of the M4 receptor. Her research interest focuses on G protein-coupled receptors, particularly on muscarinic receptor signalling and trafficking. In the future, Yingshan aspires to pursue a PhD in a related field.

Miaomiao Li is a Ph.D. candidate in the Drug Discovery Biology theme at Monash Institute of Pharmaceutical Science. She got her bachelor’s degree from Shenyang Pharmaceutical University, China, and her master’s degree from Shanghai Jiao Tong University School of Medicine, China. Her Ph.D. research focuses on investigating the regulation of the Pituitary adenylate cyclase-activating polypeptide type 1 Receptor (PAC1R) by intracellular accessory proteins, including the regulator of G protein signalling (RGS) proteins and β-arrestins. Driven by her passion for scientific innovation, she aims to advance our understanding of PAC1R regulation mechanisms and identify novel therapeutic targets for neurological disorders, such as migraine and post-traumatic stress disorder (PTSD).

Amelia is in the final year of her PhD with the Neuropharmacology research group in the Department of Biochemistry and Pharmacology at the University of Melbourne. Her research focuses on CNS innate immunity and understanding the cGAS-STING pathway and its role in driving neuroinflammation and neurodegeneration in traumatic brain injury (TBI). She has first-authored two publications during her candidature, the most recent of which was published in May in the British Journal of Pharmacology titled ‘Pharmacological inhibition of STING reduces neuroinflammation-mediated damage post-traumatic brain injury.’

Lisa is a third year PhD candidate in the School of Health, Biomedicine discipline. Her PhD studies are centred around pharmacology, examining the cellular mechanisms of a novel, proposed anti-fibrotic compound isolated from the propolis produced by the Australian Stingless bee, Tetragonula carbonaria. This compound is Tomentosenol A. Her studies have enabled her to gain experience in a broad range of biochemical and molecular laboratory techniques, cell culture and animal models. She presents her findings wherever possible, winning the best poster presentation at the 2023 Australian Society for Medical Research, Post-Graduate Student Symposium. She represented the University of the Sunshine Coast and the Centre for Bioinnovation at the 2023 AusBiotech conference and is currently finalising her first research paper for submission for publication. She is a student member of ASCEPT, ASMR and APSA. In 2024 she has been accepted to present papers at the ASCEPT, APFP & APSA Joint Congress and the UniSC Research Conference.

Dominika is a PhD candidate at the Monash Institute of Pharmaceutical Sciences. Her PhD research focuses on the development of novel mechanisms-based mathematical models that can describe and predict full time-courses of bacterial growth and resistance emergence to combat multidrug-resistant bacteria that can cause life-threatening infections. She’s passionate about investigating ways to treat resistant bacterial “superbugs” by optimising dosing regimens of currently available antibiotics in the fight against antimicrobial resistance."

Takashi Kanematsu is a professor in the Faculty of Dental Science at Kyushu University, Fukuoka Japan, where he has been since 2019. He has served as Chair of the Department of Cell Biology, Aging Science, and Pharmacology. His current research interests are in the field of Alzheimer's disease, especially the molecular mechanism of sex differences in its pathophysiology. He received his Ph.D. in Dental Science (Biochemistry) from the Kyushu University in 1994, after graduating from the Faculty of Dentistry, Kyushu University. He worked for two years as a postdoctoral fellow at Vanderbilt University, TN, USA (1995–1996), and then served as an associate professor in the Department of Biochemistry, Faculty of Dentistry, Kyushu University (1997–2008). During 2009–2018 he was Professor and Chair of the Department of Cellular & Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima Japan.

Junkai Zhang is a PhD candidate at the University of Queensland's School of Pharmacy, focusing on molecular biology, drug discovery, and pharmaceutical formulation. His academic journey began with a Bachelor of Pharmacy from Jining Medical University, where he majored in chemistry and pharmacology, followed by a Master of Pharmaceutical Industry Practice from the University of Queensland. His doctoral research aims to advance pharmaceutical sciences through the development of innovative strategies to improve drug formulation and quality assurance. Junkai is committed to contributing to the body of knowledge in pharmaceutical science and to addressing critical challenges in drug development and healthcare delivery.

Georgia Bourlotos is a currently in her second year of her PhD at Flinders University in the Neurourology Research Group. She graduated with a Bachelor of Medical Science and Honours in Medical Science from Flinders University. Her research focuses on bladder cancer and improving patient outcomes and their wellbeing. Georgia has previously published a review titled “BCG induced lower urinary tract symptoms during treatment for NMIBC - Mechanisms and management strategies” (DOI: 10.3389/fnins.2023.1327053) in Frontiers in Neuroscience. She was awarded the Flinders Health and Medical Research Institute PhD Scholarship and the Australian Governement Research Training Program Scholarship. Georgia is passionate in exploring potential pathways to reduce pain in patients suffering from superficial bladder cancer.

Charlotte Picton is an honours student studying antibacterial resistance at the Monash Institute of Pharmaceutical Sciences, Monash University, Australia. Her studies focus on investigating how different genetic mutations in bacteria affect antibiotic treatment regimens and utilising combination therapy to overcome treatment challenges. She previously completed a Bachelor of Pharmaceutical Science at Monash University.

I completed my PhD with Professor Roger Summers at the Department of Pharmacology, Monash University, where I characterised the ligand binding and signalling profiles of relaxin peptides at the human and mouse relaxin-3 receptors. I undertook postdoctoral research with Professor Michel Bouvier at the Institute for Research in Immunology and Cancer, University of Montreal, Canada from 2008 to 2012. This work involved developing intracellular signalling fingerprints for clinically used drugs targeting the β2-adrenergic receptors to better understand the links between intracellular signalling pathways and drug adverse effects, resulting in several publications in Mol Pharmacol, Nature Chem Biol and Nature Comms. This work was recently recognized as I was awarded the 2022 Early Career Researcher Award from the Monash University Faculty of Pharmacy and Pharmaceutical Sciences. From 2013-2022, I undertook postdoctoral research with Professor Arthur Christopoulos at the Monash Institute of Pharmaceutical Sciences. Here I worked within a multidisciplinary team to develop and test novel allosteric modulators targeting the M1 and M4 muscarinic acetylcholine receptors, for the treatment of the symptoms of Alzheimer’s disease and schizophrenia. I moved to SVI in 2023, to develop and characterise new drug candidates for the treatment of Alzheimer’s disease with Professor Michael Parker.

Dr. Iris Lim is an Assistant Professor in Biomedical Sciences at Bond University. Her main research interests focus on investigating the physiology and pharmacology of the lower urinary tract to discover treatments for lower urinary tract disorders. Dr. Lim is also a passionate educator and is particularly dedicated to utilising innovative tools and methods, such as gamification and game-based learning, to enhance student learning experiences and engagement.

Yifan Wang is a PhD student at the University of Queensland's School of Pharmacy in Drug Discovery, specializing in analytical chemistry, quality control, biotechnology and pharmaceutical research. Yifan has previously worked as a Design Director at Beijing Jing-Meng Cell Bio-technology Co.Ltd. He holds a Bachelor of Science from China Pharmaceutical University with a major in Marine Pharmacy and a Master of Pharmaceutical Industry Practice from the University of Queensland. His research and professional pursuits are motivated by a dedication to advancing the field of pharmaceutical sciences and enhancing the processes involved in drug development.

Sanam is a graduate pharmacist currently completing her internship at Prince of Wales Hospital in Randwick, Sydney. Her research focuses on potential roles pharmacists can play in supporting mental health care for young people, particularly within youth mental health services. She is interested in improving mental health outcomes and believes pharmacists' skills and expertise can be applied in new areas to help enhance mental health care.

Taegan Charles is currently completing a Bachelor of Science (Honours) in Pharmacology, having previously earned a Bachelor of Science in Medical Science (Neuroscience) at the University of Sydney. As a 2024 ARCS Student Scholarship recipient, Taegan has a strong background and interest in neuroscience and neuropharmacology. Her experience in science communication and media allows her to excel at translating complex scientific concepts for lay audiences, with her current Honours work centring on the benzodiazepine and vinpocetine sensitivity of GABAA receptor variants found in patients with epilepsy. This research addresses the current deficit for treatment strategies of pharmacoresistant epilepsy and examines the potential of vinpocetine as an adjunct treatment. Taegan has gained international research exposure through the Dalyell Scholars Travel Scholarship, which allowed her to study at the University of Florida. This experience expanded her scientific network and provided valuable insights into global research practices. She has also presented her work at the SIG Drug Symposium (2024) showcasing her findings thus far and demonstrating her commitment to advancing the discourse surrounding the pharmacoresistance of GABAAR variants in epilepsy.

Will is a PhD candidate entering the final year of his project. Having completed a Bachelor of Pharmacy with honours in 2018, Will is a practicing pharmacist with clinical experience in a range of community settings. His PhD project is in pharmacy ethics, exploring the responsibilities of pharmacists in the context of the opioid crisis. Will is also passionate about education, with a particular interest in teaching ethical decision-making.

Yifei Xie, Ph D., Assistant researcher of the National Center for Pharmaceutical Screening in Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College. Her research direction is new technologies and methods for drug analysis for the prevention and treatment of cardiovascular and cerebrovascular diseases and metabolic diseases. She mainly participated in research tasks such as Technology Major Special Projects and National Key R&D Plan, National Natural Science Foundation and Beijing Natural Science Foundation. In 2016, as the second person, she won the third prize of Liaoning Provincial Natural Science Award. In recent five years, 18 research papers have been published, including 6 SCI papers and 6 first and co-author papers. 16 national invention patents have been applied, including 3 invention patent authorizations.

Eman Rafhi is a third-year PhD candidate completing her Doctor of Philosophy at RMIT University in Melbourne, Australia. She holds a Bachelor’s degree in Pharmacy with Honours from RMIT University and works as a pharmacist alongside her research. Her research investigates the influence of beliefs and health literacy on medication-related outcomes in older adults. Eman's dual role as a researcher and practicing pharmacist allows her to bridge theory and practice, aiming to improve healthcare quality and medication safety for older adults.

Jocelin Chan – PhD, B. Pharm (1st class honours) is a research associate at the University of Sydney School of Pharmacy. She is also a practicing community pharmacist and a pharmacy owner. Jocelin’s research interests include drug-herb interactions; the use of Annona muricata (Graviola) in people living with cancer; quality use of complementary medicines, and the quality of herbal medicine products. She contributes to the development and review of monographs to resource healthcare professionals with evidence-based knowledge about drug-herb interactions. Her recent research includes evaluating the safety and tolerability of a herbal product (Annona muricata) through a clinical study in collaboration with Concord Cancer Centre, Sydney Australia.

Dr. Angelina Lim is a lecturer at Monash University and her key interests are simulation, authentic assessment, generative artificial intelligence, antimicrobial stewardship and paediatric endocrinology. Angelina's main expertise lies in designing and evaluating Objective Structured Clinical Examinations. Angelina has embarked on many pharmacy related career paths, starting with hospital pharmacy, then community pharmacy (still practicing), public health sector and research. She still maintains links with the Murdoch Children’s Research Institute (MCRI) working on projects in disability and paediatric endocrinology. Angelina is dedicated to teaching and education research and aims to use evidence based pedagogical approaches to drive her teaching and curriculum design.

Putin Nudaeng, a Medical student I gradated high school from Suankularb Wittayalai Thonburi school, Bangkok, Thailand. I'm currently a third-year medical student from the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Dr. Richard Ye is a Presidential Chair Professor and Associate Dean of Biomedical Research & Innovation at School of Medicine, The Chinese University of Hong Kong (CUHK) in Shenzhen, China. He received a Ph.D. in cell and integrative biology from Washington University in St. Louis and established his lab at The Scripps Research Institute and University of Illinois, where he worked on gene cloning and pharmacological characterization of formyl peptide receptors. His lab focused on innate immunity and host defense when he joined Shanghai Jiao Tong University as Dean of School of Pharmacy in 2010. In recent years, Prof. Ye’s lab used cryogenic electron microcopy to investigate the structural and functional correlation of G protein-coupled receptors including CXCR4, KSHV-GPCR, succinate receptor 1 and FPR1. He has published more than 230 research papers and is a Clarivate Highly Cited Researcher. Besides lab research, Prof. Ye serves as Associate Editor of Pharmacological Reviews.

Dr. Jeremy Jones is recognized as a leader in drug development and translational research with an historical focus in urologic oncology. He has over 20 years’ experience leading and advising research projects, including as Assistant/Associate Professor of Cancer Biology and Medical Oncology at City of Hope Comprehensive Cancer Center, Director of Oncology at Terray Therapeutics, and as President of Jones Scientific Consulting. Dr. Jones now leads AI enabled drug design and development projects and services at Simulations Plus, a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services.

Joshua is a clinical pharmacist and PhD candidate from the University of Newcastle. Joshua has a particular interest in cardio-oncology — an emerging field that focusses on mitigating cardiovascular disease secondary to cancer treatment. His research focusses primarily on pharmacist-led models of care to support people with cardiovascular disease and cancer as they transition between hospital and home. Joshua has presented his research at national and international conferences and is an active member of the International Cardio-Oncology Society (IC-OS) pharmacist working group. Joshua is also a credentialed pharmacist who continues to provide domiciliary medication management review services for his community and has broad clinical experience across both hospital and community pharmacy.

Andrew Rowland is a Professor of Clinical Pharmacology at Flinders University. He leads a highly productive team of researchers at the forefront of advancing extracellular vesicle isolation and analysis for use with human biospecimens. Andrew’s team are world leaders in the isolation and characterisation of tissue specific extracellular vesicles from blood and work closely with industry and clinicians to apply this technology to improve patient outcomes by enhancing drug efficacy and minimising harms. Andrew’s 143 peer-reviewed manuscripts have been cited more than 6,500 times, reflecting the high impact of his research, Andrew’s five-year field-weighted citation index of 7.74. Andrew holds leadership roles across multiple professional societies, including ASCEPT, where he severs on the society’s Board of Directors and is actively involved in philanthropic initiatives, through organisations including Flinders Foundation, Starlight and Tour de Cure.

Mimi Truong is a clinical pharmacist and PhD candidate at the University of Sydney. She combines her experience in community and hospital pharmacy with a passion for patient care to research ways to improve medication safety in people with kidney disease.

Jackson completed a Bachelor of Pharmaceutical Science with Honours at Monash University in 2021. He is currently a PhD Candidate in the department of Drug Discovery Biology at the Monash Institute of Pharmaceutical Sciences. Jackson has a keen interest in glutamatergic signalling within the context of neurodegenerative and neuropsychiatric disorders

Hana Amer is a Senior Pharmacist at SA Pharmacy and PhD Candidate at the University of South Australia. Hana’s PhD focuses on evaluating the effectiveness and economic consequences of collaborative pharmacist prescribing across SA public hospitals.

Dr. Ting LI is currently a Research Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, a position she has held since August 2023. Prior to joining the university, she earned her Bachelor's degree in Pharmaceutical Sciences from Wuhan University in 2012 and completed her doctoral studies at the University of Macau in 2018. Later that year, she began a five-year postdoctoral fellowship at the Rosalind and Morris Goodman Cancer Institute, McGill University, Canada. Dr. Li has published 36 scientific articles with an h-index of 22 (Google Scholar). She is the first or corresponding author (including co-corresponding) of 15 papers in leading journals, including Journal of Hematology & Oncology, Pharmacological Research, Acta Pharmacologica Sinica, Apoptosis, and Biochemical Pharmacology. Her research focuses on drug discovery and the development of strategies for aggressive neuroendocrine cancers by an interdisciplinary approach, integrating genetics, genomics, metabolomics, bioinformatics, and advanced in vitro and in vivo models.

Rory Shepherd is a Master's by Research student in Pharmacogenomics at the University of South Australia. Their research focuses on the genetic basis of antipsychotic-induced weight gain, specifically investigating the links between clozapine metabolism and metabolic syndrome in schizophrenia patients using Genome-Wide Association Studies. Rory's academic background includes a Bachelor of Health and Medical Science (Advanced) from the University of Adelaide. They have also earned a Postgraduate Diploma in Biostatistics. Currently, Rory is conducting research that combines pharmacogenomics, psychiatry, and metabolic health. Their work aims to uncover genetic factors influencing individual responses to clozapine treatment, potentially leading to more personalized and effective therapies for schizophrenia patients.

Dr. Igor Iezhitsa has over 25 years of experience in pharmacology, with a career dedicated to both academia and research. He earned his PhD in Pharmacology from Volgograd State Medical University (Russia) in 1998, followed by a Doctor of Biological Science (Dr. Sci. Biol.) degree from the same institution in 2008. From 1994 to 2000, Dr. Igor was instrumental in preclinical studies of a novel class of CNS stimulants at Volgograd State Medical University. Since then, he has conducted extensive screening and preclinical evaluation of new pharmacological compounds. In 2009, Dr. Igor joined the Faculty of Medicine at Universiti Teknologi MARA (UiTM), Malaysia, as an Associate Professor of Pharmacology. He was a key figure in establishing the Centre for Neuroscience (NeuRon) at UiTM in 2013, leading the center from 2015 to 2020. He currently serves as Professor of Pharmacology at the School of Medicine, International Medical University. Dr. Igor’s research interests include neuropharmacology, neuroprotection, toxicology, and ocular pharmacology. He has published over 110 articles in indexed journals and authored five books and chapters.

Chadchan Supsamarnwong graduated from Mahidol Wittayanusorn School and is now studying at the Faculty of Medicine, Ramathibodi Hospital.

Dr. Yuka Kohda started as a renal pharmacologist and toxicologist. She obtained her PhD at the division of pharmacology, Osaka University of Pharmaceutical Sciences. Since then, she has been fascinated by a new research discovery—“Neues.” She is a focused and diligent researcher and has collaborated with various colleges, hospitals, and companies to conduct research that has the potential to contribute to the advancement of healthcare. She currently studies oxidative stress at the Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University. Oxidative stress plays an important role in the onset and progression of various diseases. Although we the COVID-19 pandemic has ended, the obesity and diabetes pandemic have shown no signs of subsiding. Dr. Yuka Kohda believes that prevention of obesity-induced diabetes secondary is critical in many countries. We can learn about “Neues“ at the ASCEPT, APFP, and APSA Joint Congress 2024, Melbourne.

Dr John Mach is a Research Fellow and Laboraotry Manager who leads the basic science branch of the Laboratory of Ageing and Pharmacology, Kolling Institute, University of Sydney and Royal North Shore Hospital. He studied his undergraduate BSc with Honours in pharmacology at UNSW and earned his PhD at USYD, supervised by Professor Sarah Hilmer, using preclinical models to investigate risk of drug induced liver injury in old age. His work now focuses on utilising preclinical models to understand the risks of multiple concurrent medicines in old age, aiming to inform optimal medication use for older people. He strives to understand the mechanism, and identify risk factors and biomarkers that modulate an older individuals functional wellbeing.

Dr Suong Ngo has been a member of ASCEPT since 1999 and actively contributed to ASCEPT Annual Scientific Meetings, AGMs and Education Forum, Symposium. Suong has been working closely with Fellow ASCEPT educators on developing the core concepts of pharmacology education and is part of the Australian and New Zealand Core Concepts Group (CC-PEG) (White et al., 2021; Santiago, Davis et al., 2021, Guilding et al., 2023) and was one of the attendees at the Inaugural Core Concepts of Pharmacology Education Workshop, held at Monash University Prato Centre, Italy in July 2022 as part of the IUPHAR Education project. Her current research focuses on the anti-cancer stem cell effects of cruciferous vegetables’ constituents. Overall, she has published over 50 research papers in high quality specialised scientific journals, including in BJP and JPRP. Suong is a Committee Member of the ASCEPT Equity, Diversity and Inclusion Committee.

Vincent is a pharmacist and pharmacy academic with backgrounds in pharmacy, public health and biomedical sciences. He is currently the Assistant Associate Dean (Pharmacy) at RMIT University and also holds appointments at Austin Health and Queensland University of Technology. His research focuses on pharmacy practice/quality use of medicine, pharmacist roles and interventions, and pharmacotherapeutics.

Dr Hellyer is a senior postdoctoral fellow in the Endocrine and Neuropharmacology Laboratory at the Monash Institute of Pharmaceutical Sciences (MIPS) in Melbourne, Australia. He is an emerging independent researcher with an interest in G protein-coupled receptors (GPCRs), and how they contribute to the pathology of neurological disorders. Dr Hellyer has established a track record in analytical GPCR pharmacology, including biased agonism and modulation of Class C GPCRs in recombinant cells and primary brain cell cultures

HuangJu Tu is a postdoctoral fellow at Taipei Medical University. His research focuses on neuroscience and cancer biology.

Dr. Chihiro Tohda was earned Ph.D. (Pharmaceutical Science) from Hokkaido University in 1994. She worked as a Research Fellowship for Young Scientists of JSPS and became an Assistant Professor in Research Institute for Wakan-yaku, Toyama Medical and Pharmaceutical University. She moved to Research Center for Ethnomedicines, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University in 1996. From Nov. 1997, she worked at National Institute of Health (USA) for 4 months. She became an Associate Professor and Head of Division at of Neuromedical Science, Institute of Natural Medicine, University of Toyama in 2010, and a Full Professor and Head of Section of Neuromedical Science in 2017. Current Position is a Full Professor/Vice Director of Institute of Natural Medicine, University of Toyama. She is engaged in research primarily focused on natural medicines, aiming to develop novel therapeutic approaches for refractory neurodegenerative diseases such as dementia, spinal cord injury, degenerative cervical myelopathy and glaucoma. She is also advancing clinical studies based on the outcomes of foundational research, with a keen awareness towards eventual societal implementation of our findings.

My name is Tien-Yun Lan, and I am currently a Ph.D. student at the Institute of Pharmacology, National Yang Ming Chiao Tung University, Taiwan. My research primarily focuses on pharmacology related to kidney diseases, with a particular emphasis on acute kidney injury (AKI). In July 2024, I published a study exploring a novel potential therapeutic agent for ischemia-reperfusion-induced acute kidney injury. As I move forward in my research career, I am expanding my focus to the discovery of potential therapeutic agents for diabetes and cardiovascular diseases—two major global health concerns.

Shu Watanuki graduated from the School of Veterinary Medicine at Hokkaido University in 2023 and obtained a veterinary license. Currently, he is affiliated with the Laboratory of Pharmacology at the Faculty of Veterinary Medicine, Hokkaido University, where he conducts research on the central nervous system. As a second author, he contributed to the publication "Short-term memory impairment following recovery from systemic inflammation induced by lipopolysaccharide in mice" (DOI: 10.3389/fnins.2023.1273039). Additionally, he has received three awards at academic conferences in Japan.

I am a PhD candidate at QUT, as well as a registered pharmacist and higher education academic in Sri Lanka. My research interests are centered on pharmacy practice-based research

Eleanor is a 2nd year PhD candidate in the Department of Pharmacology at Monash University’s Biomedical Discovery Institute. After completing her Honours degree in 2022, she commenced her PhD in 2023 under the supervision of Dr Mark Del Borgo, Associate Professor Meredith O’Keeffe and Professor Max Cryle. Combining her background in immunology and pharmacology, she is researching the use of dendritic cell-based extracellular vesicle mimetics for indications in vaccination and cancer. She hopes to develop a platform for utilising the innate ability of dendritic cells to transfer antigen to promote an immune response tailored to the target disease.

Hi, my name Julyan and I’m a PhD candidate in the School of Biomedical Sciences at the University of Western Australia, and based at Harry Perkins Institute of Medical Research. My research focus is on novel receptor heteromers formed between G protein-coupled receptors and scavenger receptors, and their role in the receptor biology of atherosclerosis.

Bella is a final year Bachelor of Pharmacy student at The University of Sydney. This year she completed her honours degree under the supervision of Professor Christine Lu and Dr Edwin Tan. Her research focuses on investigating the opportunity for pharmacogenetic testing implementation in Australia

Benson is a PhD candidate at the Sydney Pharmacy School. His primary areas of research interest include clinical pharmacy, pharmacoepidemiology and health services research. He is also a registered pharmacist with experience in both community and hospital pharmacy

Amy is a recent graduate of the Bachelor of Pharmacy (Honours) program at the University of Sydney, with a keen interest in medication safety and public health. For her Honours research project, Amy focused on safe medicine disposal practices, specifically exploring ways to enhance community pharmacists' role in educating the public about proper disposal methods. In 2025, Amy is set to commence her role as a hospital intern pharmacist, where she aims to apply her research experience in clinical settings and further develop her professional skills.

Dr Sellers has forged a distinguished academic career combining research and teaching at leading universities and hospitals in the United Kingdom. Focussing her research interests on the physiological and pharmacological function of smooth muscle, she has collaborated with fellow research scientists to relate her findings to medical disorders such as overactive bladder function and the complications of diabetes. Complementing her research portfolio, Dr Sellers has taught undergraduate and postgraduate subjects at Sheffield Hallam University, the University of Sheffield and the University of Manchester prior to joining Bond University's Faculty of Health Sciences and Medicine in 2009